Fig. 1 · Structure

Documents & Downloads

Vilazodone Hydrochloride

Cat. No. A11604 CAS 163521-08-2

serotonin transporter (SER) inhibitor

Vilazodone Hydrochloride (EMD 68843 Hydrochloride) is a serotonin transporter (SER) inhibitor and 5-HT1A receptor partial agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
sPLA2  
5-HT1A Receptor  

Vilazodone Hydrochloride Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Vilazodone Hydrochloride from 3 published references. In vitro models include fluorescently labeled SERT; HEK293 cells.

Vilazodone Hydrochloride In Vitro Studies

Following incubation with fluorescently labeled SERT, Vilazodone had a KD in Na+ of 1.0 [0.4; 2.3] nM. In HEK293 cells treated at 5 μM for 16 h, Vilazodone produced significantly higher toxicity than vehicle treatment, while cell death did not exceed 50%. In intact COS-7 cells transiently expressing SERT WT, Vilazodone inhibited [3H]5-HT transport with an IC50 around 1 nM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Vilazodone Affinity for Purified SERT

Cell-based study · fluorescently labeled SERT [1]

Fluorescently labeled SERT was incubated with Vilazodone for 2 h at RT. The KD for Vilazodone in Na+ was 1.0 [0.4; 2.3] nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
vilazodone affinity for purified SERTKD 1.0 [0.4; 2.3] nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
16 serial-dilution concentrations from 0.012 nM to 400 nM
Exposure duration
2 h at RT
Method
incubated
Vehicle
20 mM HEPES, 0.05% GDN, 0.4% DMSO, and 150 mM NaCl
Methods and source locations

Compound reported in the paper: Vilazodone

The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.

Results > SERT binds vilazodone Na+-independently with nM affinity (S70, S73, S74); Methods > Fluorescence spectral shift binding experiments (S217, S222, S223, S227); Fig. 5 legend (S289)

vilazodone affinity for purified SERT: vilazodone affinity for purified SERT; comparator: target alone — Results > SERT binds vilazodone Na+-independently with nM affinity (S70, S74)

Vilazodone Toxicity in HEK293 Cells

Cell-based study · HEK293 cells [2]

HEK293 cells were treated with Vilazodone at 5 μM for 16 h. Toxicity was significantly higher than in vehicle-treated cells, while cell death did not exceed 50%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of pyknotic nuclei per fieldpercentage of pyknotic nuclei cell death did not exceed 50%[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
16 h treatment
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Vilazodone

The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.

Results > PPI Modulatory Activity of the FDA-Approved Drugs (S53); 6 legend (S339, S341)

percentage of pyknotic nuclei per field: percentage of pyknotic nuclei per field; comparator: vehicle-treated cells — Results > PPI Modulatory Activity of the FDA-Approved Drugs (S53); 6 legend (S339)

Vilazodone Inhibition of SERT WT Transport

Cell-based study · intact COS-7 cells transiently expressing SERT WT [1]

Vilazodone was added to intact COS-7 cells transiently expressing SERT WT. It inhibited [3H]5-HT transport by SERT WT with an IC50 around 1 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
[3H]5-HT transportIC50 IC50 around 1 nM[1]

Literature-Reported Treatment Conditions

Exposure duration
30 min prior to the addition of 50 µL 12.25 nM [3H]5-HT; 3 min of incubation
Method
added to cells
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Vilazodone

The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.

Results > Mutations in the allosteric site do not decrease the inhibition potency of vilazodone (S8); Methods > [3H]5-HT uptake experiments (S146, S148, S151); Fig. 1 legend (S254)

[3H]5-HT transport: [3H]5-HT transport; comparator: WT in absence of inhibitor — Results > Mutations in the allosteric site do not decrease the inhibition potency of vilazodone (S8)

Vilazodone Hydrochloride In Vivo Studies

Vilazodone Hydrochloride was administered at 10 mg/kg i.p. to adult male Sprague–Dawley rats with stepping deficits in the 6-OHDA/VIL/LD group. AIM counts were significantly reduced in this group, with less than 10% of total counts compared to the 6-OHDA/Veh/LD group. [3]

Reduced AIM Counts in Rats With Stepping Deficits

Animal study · Adult male Sprague–Dawley rats; 6-OHDA-infused rats with stepping deficits; 6-OHDA/VIL/LD, n = 8 [3]

In adult male Sprague–Dawley rats with stepping deficits, Vilazodone Hydrochloride at 10 mg/kg i.p. was evaluated in the 6-OHDA/VIL/LD group against the 6-OHDA/Veh/LD group. AIM counts were significantly reduced in the 6-OHDA/VIL/LD group, with less than 10% of total counts compared to the 6-OHDA/Veh/LD group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
3-day averages in week 2 for axial, limb, orolingual, and total AIMsAIM counts less than 10% of total counts[3]

Conditions shared by the study groups

Route
i.p.
Treatment course
30 min after receiving an injection of vilazodone HCl (VIL); once daily on 5 days (Mon–Fri) for two weeks
Vehicle
10% Cremophor EL in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vilazodone Hydrochloride 10 mg/kg6-OHDA/Veh/LD, n = 6AIM counts were significantly reduced in the 6-OHDA/VIL/LD group; These rats showed less than 10% of total counts compared to those of the 6-OHDA/Veh/LD group.[3]
Vilazodone Hydrochloride 10 mg/kg
Model: Adult male Sprague–Dawley rats; 6-OHDA-infused rats with stepping deficits; 6-OHDA/VIL/LD, n = 8
Methods and source locations

Compound reported in the paper: Vilazodone Hydrochloride; Compound label in the paper: Vilazodone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Animals (S1); 2. Materials and Methods > 2.2. 6-OHDA Lesions (S4, S5); 2. Materials and Methods > 2.4. Drug Treatment (S14, S16); 3. Results > 3.1. Behavioral Effects of Vilazodone (S52, S54, S55)

3-day averages in week 2 for axial, limb, orolingual, and total AIMs: 3-day averages in week 2 for axial, limb, orolingual, and total AIMs; comparator: 6-OHDA/Veh/LD, n = 6 — 3. Results > 3.1. Behavioral Effects of Vilazodone (S52, S54, S55)

Vilazodone Hydrochloride 10 mg/kg · 2. Materials and Methods > 2.4. Drug Treatment (S14, S16); 3. Results > 3.1. Behavioral Effects of Vilazodone (S54, S55)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 163521-08-2
Applications serotonin transporter (SER) inhibitor
Formula C26H28ClN5O2
Molecular Weight 477.99
Synonyms EMD 68843; EMD68843 (Hydrochloride); SB659746A; SB-659746A (Hydrochloride)
SMILES
NC(C1=CC2=C(C=CC(N3CCN(CCCCC4=CNC5=CC=C(C=C54)C#N)CC3)=C2)O1)=O.[H]Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 84 mg/mL (175.74 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Vilazodone Hydrochloride Research References

  1. [1] Kalenderoglou IE, Nygaard A, Vogt CD, et al. Structural basis of vilazodone dual binding mode to the serotonin transporter. Nat Commun (2025). PMID: 41253806 DOI: 10.1038/s41467-025-65202-3 Source material
  2. [2] Muñoz-Reyes D, Aguado L, Arroyo-Urea S, et al. FDA Drug Repurposing Uncovers Modulators of Dopamine D2 Receptor Localization via Disruption of the NCS-1 Interaction. J Med Chem (2025). PMID: 41211723 DOI: 10.1021/acs.jmedchem.5c01626 Source material
  3. [3] Altwal F, Moon C, West AR, et al. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells (2020). PMID: 33050305 DOI: 10.3390/cells9102265 Source material

Added to your cart

View Cart Checkout
Loading...